Enovix Revenue Jumps 85%, But Net Loss Widens on Soaring Interest Costs

TL;DR

**Enovix is burning cash to scale, and while revenue is up, the ballooning debt and net loss make it a high-risk, high-reward play.**

AI Summary

Enovix Corp (ENVX) reported a significant increase in revenue for the fiscal quarter ended September 28, 2025, reaching $7.99 million, up from $4.32 million in the prior year, representing an 85% increase. Year-to-date revenue also grew to $20.56 million from $13.36 million. Despite revenue growth, the company's net loss widened to $53.71 million for the quarter, compared to a net loss of $22.54 million in the same period last year. This expanded loss was primarily driven by a substantial increase in interest expense, which surged to $11.77 million from $1.72 million, and a decrease in the change in fair value of common stock warrants, which contributed $1.87 million compared to $29.90 million previously. Operating expenses decreased year-to-date to $136.87 million from $205.06 million, largely due to the absence of the $41.81 million restructuring cost incurred in the prior year. The company's cash and cash equivalents increased to $335.50 million as of September 28, 2025, from $272.87 million at December 29, 2024, bolstered by $360 million in proceeds from convertible senior notes and loan borrowing. Total assets grew to $913.71 million from $527.17 million, while long-term debt increased significantly to $518.35 million from $169.82 million.

Why It Matters

Enovix's substantial revenue growth, coupled with a widening net loss, presents a mixed signal for investors. The 85% quarterly revenue increase indicates strong market interest in their next-generation Li-ion battery cells, particularly with the anticipated AI-1 platform launch. However, the dramatic rise in interest expense and long-term debt to $518.35 million suggests aggressive financing to fuel growth, which could strain future profitability and cash flow. Competitively, if Enovix can successfully scale its manufacturing at Fab2 in Malaysia and its South Korea facility, it could gain a significant edge in energy density over rivals, impacting the smartphone, smart eyewear, and EV markets. Employees and customers will be watching for successful product commercialization and sustained operational stability amidst these financial dynamics.

Risk Assessment

Risk Level: high — The risk level is high due to a significant increase in net loss to $53.71 million for the quarter and a substantial rise in long-term debt to $518.35 million from $169.82 million. This indicates heavy reliance on financing to fund operations and growth, which could lead to future liquidity challenges if commercialization efforts do not rapidly generate sufficient profits.

Analyst Insight

Investors should closely monitor Enovix's progress on its AI-1 platform and manufacturing scale-up at Fab2 in Malaysia. While the revenue growth is positive, the increasing debt and net loss necessitate a cautious approach. Consider waiting for clearer signs of profitability and reduced reliance on debt financing before making a significant investment.

Financial Highlights

debt To Equity

1.74

revenue

$7.99M

operating Margin

-587.9%

total Assets

$913.71M

total Debt

$518.35M

net Income

-$53.71M

gross Margin

17.5%

cash Position

$335.50M

revenue Growth

+85%

Key Numbers

• $7.99M — Quarterly Revenue (Increased 85% from $4.32M in Q3 2024)
• $20.56M — Year-to-Date Revenue (Increased from $13.36M in YTD Q3 2024)
• $53.71M — Quarterly Net Loss (Widened from $22.54M in Q3 2024)
• $121.75M — Year-to-Date Net Loss (Improved from $184.78M in YTD Q3 2024)
• $11.77M — Quarterly Interest Expense (Increased from $1.72M in Q3 2024)
• $518.35M — Long-Term Debt (Increased from $169.82M at Dec 29, 2024)
• $335.50M — Cash and Cash Equivalents (Increased from $272.87M at Dec 29, 2024)
• $360M — Proceeds from Convertible Senior Notes and Loan Borrowing (Key financing activity year-to-date)
• $45.29M — Purchase of Capped Calls (Financing activity year-to-date)
• 215.82M — Shares Outstanding (As of November 3, 2025)

Key Players & Entities

• Enovix Corp (company) — Registrant
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Select Market (market) — Exchange where common stock is registered
• Private Securities Litigation Reform Act of 1995 (law) — Governs forward-looking statements
• Fab2 (location) — Manufacturing facility in Malaysia
• South Korea (location) — Location of acquired facility and asset expansion
• SolarEdge (company) — Source of asset purchase
• AI-1 platform (product) — Next-generation battery platform
• Delaware (location) — State of incorporation
• Silicon Valley (location) — Headquarters location

FAQ

Risk Factors

• Increased Interest Expense and Debt Burden [high — financial]: The company's interest expense surged to $11.77 million for the quarter ended September 28, 2025, from $1.72 million in the prior year. This is directly linked to a significant increase in long-term debt, which rose to $518.35 million from $169.82 million. This growing debt load and associated interest payments pose a substantial financial risk, potentially impacting profitability and cash flow.
• Dependence on New Technology and Market Adoption [high — operational]: Enovix's success is heavily reliant on the successful commercialization and widespread adoption of its novel battery technology. Any delays in production, manufacturing challenges, or failure to gain market traction could significantly hinder revenue growth and profitability. The company is still in the early stages of scaling production.
• Widening Net Loss Despite Revenue Growth [medium — financial]: Although revenue increased by 85% to $7.99 million in the quarter, the net loss widened to $53.71 million from $22.54 million year-over-year. This indicates that the cost of revenue and operating expenses, particularly the surge in interest expense, are outpacing revenue gains, raising concerns about the company's path to profitability.
• Competition in the Battery Market [medium — market]: The battery market is highly competitive, with established players and emerging technologies vying for market share. Enovix faces competition from companies with significant resources and existing customer relationships, which could make market penetration challenging.
• Supply Chain and Manufacturing Scalability [medium — operational]: Scaling manufacturing operations to meet potential demand for its advanced battery technology presents significant operational challenges. Disruptions in the supply chain, quality control issues, or difficulties in achieving efficient mass production could impede the company's growth trajectory.
• Reliance on Financing Activities [medium — financial]: The company has relied on substantial financing, including $360 million from convertible senior notes and loan borrowing, to fund its operations and growth. Future funding needs and the terms of these financing arrangements, including potential dilution from convertible notes, represent a financial risk.
• Environmental and Safety Regulations [low — regulatory]: The manufacturing of batteries involves processes and materials subject to stringent environmental and safety regulations. Non-compliance or changes in these regulations could lead to increased costs, operational disruptions, or penalties.

Industry Context

Enovix operates in the highly competitive and rapidly evolving battery technology sector, aiming to disrupt the market with its silicon-anode battery technology. Key industry trends include the increasing demand for higher energy density, faster charging capabilities, and improved safety in batteries for consumer electronics, electric vehicles, and other applications. The company faces competition from established lithium-ion battery manufacturers and other innovators developing next-generation battery chemistries.

Regulatory Implications

As a manufacturer of advanced battery technology, Enovix is subject to various environmental, health, and safety regulations related to material sourcing, manufacturing processes, and product disposal. Compliance with these regulations is crucial to avoid penalties and maintain operational continuity. Furthermore, any changes in international trade policies or tariffs could impact the cost of raw materials and finished goods.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-28: End of Fiscal Quarter and Year-to-Date Reporting Period — Marks the period for which the financial results in the 10-Q are reported, showing significant revenue growth but a widening net loss.
• 2025-11-03: Shares Outstanding Reported — Provides context for per-share metrics and potential dilution, with 215.82 million shares outstanding.
• 2025-09-29: Prior Year Quarter End — Used as a comparative period for revenue growth and net loss analysis, highlighting an 85% revenue increase but a wider net loss.
• 2024-12-29: Prior Year End Balance Sheet Date — Used for comparison of asset and liability changes, showing substantial growth in assets and long-term debt.

Glossary

Change in fair value of common stock warrants

This represents the unrealized gain or loss from the fluctuation in the market value of outstanding warrants, which are financial instruments giving the holder the right to purchase stock at a specific price. (A significant decrease in this item from $29.90 million to $1.87 million in the quarter contributed to the wider net loss, masking underlying operational performance.)

Convertible senior notes

Debt securities that can be converted into a predetermined amount of the issuer's equity (stock) at certain times during their life. (Enovix raised $360 million from these notes, which is a key financing activity that bolstered cash but also introduces potential future dilution.)

Accumulated deficit

The cumulative net losses of a company since its inception, less any net gains. It represents the total losses that have not been offset by profits. (Enovix has a substantial accumulated deficit of $942.84 million as of September 28, 2025, underscoring its history of unprofitability.)

Warrant liability

The fair value of outstanding warrants that are classified as liabilities on the balance sheet, typically due to features that require cash settlement. (The warrant liability decreased from $28.38 million to $16.63 million, reflecting changes in warrant valuations and potentially impacting the statement of operations.)

Treasury stock

Stock that a company has repurchased from the open market. It is recorded at cost and reduces total stockholders' equity. (Enovix reported $58.39 million in treasury stock as of September 28, 2025, indicating a recent share repurchase activity.)

Goodwill

An intangible asset that arises when one company acquires another company for a price greater than the fair market value of its net assets. (Enovix has $12.22 million in goodwill, which has remained constant, suggesting no significant acquisitions in the reporting periods.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Enovix has demonstrated impressive revenue growth, with quarterly revenue increasing by 85% to $7.99 million and year-to-date revenue rising to $20.56 million. However, this top-line growth has been overshadowed by a significantly widened net loss, which grew from $22.54 million to $53.71 million in the quarter. This expansion in losses is primarily driven by a substantial increase in interest expense, which surged from $1.72 million to $11.77 million, and a decrease in the positive impact from warrant fair value changes. While operating expenses have decreased year-to-date due to the absence of prior year restructuring costs, the overall financial picture shows increased financial leverage and a greater reliance on debt financing.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ENVX The Nasdaq Global Select

Filing Documents

• envx-20250928.htm (10-Q) — 1770KB
• envx10q-q320250928exx311.htm (EX-31.1) — 11KB
• envx10q-q320250928exx312.htm (EX-31.2) — 11KB
• envx10q-q320250928exx321.htm (EX-32.1) — 6KB
• envx10q-q320250928exx322.htm (EX-32.2) — 6KB
• envx-20250928_g1.jpg (GRAPHIC) — 10KB
• 0001828318-25-000310.txt ( ) — 8576KB
• envx-20250928.xsd (EX-101.SCH) — 45KB
• envx-20250928_cal.xml (EX-101.CAL) — 88KB
• envx-20250928_def.xml (EX-101.DEF) — 276KB
• envx-20250928_lab.xml (EX-101.LAB) — 705KB
• envx-20250928_pre.xml (EX-101.PRE) — 507KB
• envx-20250928_htm.xml (XML) — 1171KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of September 28, 2025 and December 29, 2024 1 Condensed Consolidated Statements of Operations for the fiscal quarters ended and fiscal years-to-date ended September 28, 2025 and September 29, 2024 2 Condensed Consolidated Statements of Comprehensive Income (Loss) for the fiscal quarters and fiscal years-to-date ended September 28, 2025 and September 29, 2024 3 Condensed Consolidated Statements of Changes in Stockholders' Equity for the fiscal quarters and fiscal years-to-date ended September 28, 2025 and September 29, 2024 4 Condensed Consolidated Statements of Cash Flows for the fiscal years-to-date ended September 28, 2025 and September 29, 2024 6 Notes to Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 3. Quantitative and Qualitative Disclosure about Market Risks 41 Item 4.

Controls and Procedures

Controls and Procedures 41 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities 74 Item 3 Defaults Upon Senior Securities 74 Item 4 Mine Safety Disclosures 74 Item 5 Other Information 74 Item 6. Exhibits 75

Signatures

Signatures 77 Table of Contents

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements contained in this Quarterly Report that are not purely historical are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance and can be identified by words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, will, would and similar expressions that convey uncertainty about future events or outcomes. In addition, any statements that refer to projections, forecasts, management's expectations, hopes, beliefs, intentions or strategies regarding the future, are forward-looking statements. Examples of forward-looking statements in this Quarterly Report include, without limitation, statements about: our future operating results, financial position, growth opportunities and guidance, and our anticipation that changes in the global trade environment do not pose a material risk to our outlook; our commercialization plans, strategy and product development roadmap, including the AI-1 platform launch, AI Class of batteries, and the readiness, performance, timing, and customer qualification of our AI-1 smartphone battery, other batteries under development from the AI-1 platform, and the design of our next battery technology node; our manufacturing strategy, including scale-up and operational readiness, including at Fab2 in Malaysia, our assets and facility expansion in South Korea, and the anticipated benefits of the SolarEdge asset purchase, and our ability to enhance per-zone capacity and reduce switching time between configurations; our benchmarking of key battery metrics such as energy density and fast charge and competitive positioning, including our ability to maintain and expand a performance lead over other silicon-d

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ENOVIX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share and par value amounts) September 28, 2025 December 29, 2024 Assets Current assets: Cash and cash equivalents $ 335,502 $ 272,869 Short-term investments 223,316 — Accounts receivable, net 4,631 4,566 Notes receivable, net 2,412 4 Inventory 15,224 7,664 Prepaid expenses and other current assets 7,547 9,903 Total current assets 588,632 295,006 Property and equipment, net 174,585 167,947 Long-term investments 89,451 — Customer relationship intangibles and other intangibles, net 32,827 36,394 Operating lease, right-of-use assets 11,774 13,479 Goodwill 12,217 12,217 Other assets, non-current 4,223 2,126 Total assets $ 913,709 $ 527,169 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 21,311 $ 9,492 Accrued expenses 8,928 19,843 Accrued compensation 7,214 8,228 Short-term debt 10,151 9,452 Deferred revenue 7,689 3,650 Other liabilities 5,281 3,036 Total current liabilities 60,574 53,701 Long-term debt, net 518,348 169,820 Warrant liability 16,632 28,380 Operating lease liabilities, non-current 11,413 13,293 Deferred revenue, non-current 300 3,774 Deferred tax liability 9,325 8,784 Other liabilities, non-current 14 14 Total liabilities 616,606 277,766 Commitments and Contingencies (Note 9) Stockholders' equity: Common stock, $ 0.0001 par value; authorized shares of 1,000,000,000 ; issued and outstanding shares of 215,367,757 and 190,559,335 as of September 28, 2025 and December 29, 2024, respectively 22 19 Additional paid-in-capital 1,296,114 1,067,951 Treasury stock, at cost ( 58,385 ) — Accumulated other comprehensive loss ( 658 ) ( 143 ) Accumulated deficit ( 942,837 ) ( 821,086 ) Total Enovix stockholders' equity 294,256 246,741 Non-controlling interest 2,847 2,662 Total equity 297,103 249,403 Total liabilities and equity $ 913,709 $ 527,169 See accompanying note